Condition (MeSH)
Cellulitis
ClinicalTrials.gov lists 167 trials for Cellulitis or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 9.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
157 of the 167 trials are tagged with Cellulitis itself; the rest are tagged with a narrower condition beneath it.
When did Cellulitis trials start? (29)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 15
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 4 |
| 2024 | 6 |
| 2023 | 3 |
| 2022 | 4 |
| 2021 | 5 |
| 2020 | 8 |
| 2019 | 7 |
| 2018 | 9 |
| 2017 | 4 |
Showing 10 of 29 earlier years.
No forecast is made for this condition: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 18 months across 122 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cellulitis trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 20 |
| Phase 2/3 | 3 |
| Phase 3 | 34 |
| Phase 4 | 23 |
| Not applicable | 48 |
| Observational | 31 |
| Expanded access | 1 |
How many Cellulitis trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 5 |
| Recruiting | 9 |
| Active, not recruiting | 1 |
| Completed | 120 |
| Terminated | 10 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cellulitis trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| GlaxoSmithKline | 9 |
| Pfizer | 4 |
| 59th Medical Wing | 3 |
| Durata Therapeutics Inc., an affiliate of Allergan plc | 3 |
| Forest Laboratories | 3 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Cellulitis? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Flucloxacillin | 4 |
| Dalbavancin | 4 |
| Aztreonam | 4 |
| Tigecycline | 3 |
| Ceftaroline | 3 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Vancomycin 1.1% | 9 |
| Zyvox - linezolid | 9 |
| Daptomycin 6mg/kg/day | 7 |
| Clindamycin Gel | 5 |
| Cephalexin suspension (Keflex) | 5 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Cellulitis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cellulitis | 61 | 15 |
| Infection | 36 | 4 |
| Osteomyelitis | 30 | 6 |
| Pneumonia | 17 | 11 |
| Abscess | 14 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Cellulitis? (115)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Antibiotic Timing and Progression to Septic Shock Among Patients in the ED With Suspected Infection. | Chest | 2022 | Yes |
| Corticosteroids for periorbital and orbital cellulitis. | The Cochrane database of systematic reviews | 2021 | Yes |
| The Skin Microbiota in Patients Hospitalized for Cellulitis and Association With Outcome. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2019 | Yes |
| Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial. | The Lancet. Infectious diseases | 2019 | Yes |
| Intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis: a cost-effectiveness analysis. | The Lancet. Infectious diseases | 2019 | Yes |
Showing 5 of 115 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.